Crossmark

Pharmacokinetics of XEN496, a Novel Pediatric Formulation of Ezogabine, Under Fed and Fasted Conditions: A Phase 1 Trial

Published Online: 2022-04-05

Published Print: 2022-06

Authors

Namdari, Rostam

Luzon, Constanza

Cadieux, Jay A.

Leung, Jennifer

Beatch, Gregory N.
Funding

Funding for this research was provided by:

Xenon Pharmaceuticals
License Information

Text and Data Mining valid from 2022-04-05

Version of Record valid from 2022-04-05
More Information

Article History

Received: 13 February 2022

Accepted: 9 March 2022

First Online: 5 April 2022

Document is current